Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: OTC US
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

TapImmune Inc

+ Add to Watchlist

TPIV:US

0.2300 USD 0.0151 7.03%

As of 20:10:02 ET on 03/27/2015.

Snapshot for TapImmune Inc (TPIV)

Open: 0.2149 Day's Range: 0.2125 - 0.2650 Volume: 211,777
Previous Close: 0.2149 52wk Range: 0.1210 - 4.1800 1-Yr Rtn: -94.40%

Stock Chart for TPIV

No chart data available.
  • TPIV:US 0.2300
  • 1D
  • 1M
  • 1Y
0.2149
Interactive TPIV Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TPIV

Current P/E Ratio (ttm) -
Estimated P/E(-) -
Relative P/E vs. SPX -
Earnings Per Share (ttm) -1.7998
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 7.51
Shares Outstanding (M) 32.64
30 Day Average Volume 209,656
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TPIV

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for TPIV

TapImmune, Inc. is a biotechnology company that discovers and develops immunotherapeutics aimed at the treatment and eradication of cancer. The Company also develops therapies for infectious diseases, autoimmune disorders, and transplant tissue rejection.

Glynn WilsonChairman/CEO/CFO/SecretaryMark ReddishVP:Product Development
Thad MorrisInvestor Relations
More Company Profile & Key Executives for TPIV

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil